Literature DB >> 11817319

Uremic toxicity: present state of the art.

R Vanholder1, A Argilés, U Baurmeister, P Brunet, W Clark, G Cohen, P P De Deyn, R Deppisch, B Descamps-Latscha, T Henle, A Jorres, Z A Massy, M Rodriguez, B Stegmayr, P Stenvinkel, M L Wratten.   

Abstract

The uremic syndrome is a complex mixture of organ dysfunctions, which is attributed to the retention of a myriad of compounds that under normal condition are excreted by the healthy kidneys (uremic toxins). In the area of identification and characterization of uremic toxins and in the knowledge of their pathophysiologic importance, major steps forward have been made during recent years. The present article is a review of several of these steps, especially in the area of information about the compounds that could play a role in the development of cardiovascular complications. It is written by those members of the Uremic Toxins Group, which has been created by the European Society for Artificial Organs (ESAO). Each of the 16 authors has written a state of the art in his/her major area of interest.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11817319

Source DB:  PubMed          Journal:  Int J Artif Organs        ISSN: 0391-3988            Impact factor:   1.595


  55 in total

1.  Cerebrocellular swelling in the presence of uraemic guanidino compounds: ameliorative effects of taurine.

Authors:  R O Law
Journal:  Neurochem Res       Date:  2005-12       Impact factor: 3.996

2.  Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins.

Authors:  Kyra J Barnes; Andrew Rowland; Thomas M Polasek; John O Miners
Journal:  Eur J Clin Pharmacol       Date:  2014-06-24       Impact factor: 2.953

Review 3.  AKI associated with cardiac surgery.

Authors:  Robert H Thiele; James M Isbell; Mitchell H Rosner
Journal:  Clin J Am Soc Nephrol       Date:  2014-11-06       Impact factor: 8.237

Review 4.  Home haemodialysis and uraemic toxin removal: does a happy marriage exist?

Authors:  Raymond Vanholder; Sunny Eloot; Nathalie Neirynck; Wim Van Biesen
Journal:  Nat Rev Nephrol       Date:  2012-08-28       Impact factor: 28.314

5.  Effects of amino acids and albumin on erythropoietin carbamoylation.

Authors:  Kyubok Jin
Journal:  Clin Exp Nephrol       Date:  2012-12-11       Impact factor: 2.801

Review 6.  Clinical and experimental use of probiotic formulations for management of end-stage renal disease: an update.

Authors:  Alessandro Di Cerbo; Federica Pezzuto; Lucia Palmieri; Valentina Rottigni; Tommaso Iannitti; Beniamino Palmieri
Journal:  Int Urol Nephrol       Date:  2013-04-13       Impact factor: 2.370

7.  Increased levels of total P-Cresylsulphate and indoxyl sulphate are associated with coronary artery disease in patients with diabetic nephropathy.

Authors:  Cheng-An Chiu; Li-Fen Lu; Teng-Hung Yu; Wei-Chin Hung; Fu-Mei Chung; I-Ting Tsai; Chih-Ying Yang; Chia-Chang Hsu; Yung-Chuan Lu; Chao-Ping Wang; Yau-Jiunn Lee
Journal:  Rev Diabet Stud       Date:  2011-02-10

8.  The case for routine parathyroid hormone monitoring.

Authors:  Stuart M Sprague; Sharon M Moe
Journal:  Clin J Am Soc Nephrol       Date:  2012-10-04       Impact factor: 8.237

Review 9.  Mechanisms of cardiovascular complications in chronic kidney disease: research focus of the Transregional Research Consortium SFB TRR219 of the University Hospital Aachen (RWTH) and the Saarland University.

Authors:  Nikolaus Marx; Heidi Noels; Joachim Jankowski; Jürgen Floege; Danilo Fliser; Michael Böhm
Journal:  Clin Res Cardiol       Date:  2018-05-04       Impact factor: 5.460

Review 10.  Role of the Gut Microbiome in Uremia: A Potential Therapeutic Target.

Authors:  Ali Ramezani; Ziad A Massy; Björn Meijers; Pieter Evenepoel; Raymond Vanholder; Dominic S Raj
Journal:  Am J Kidney Dis       Date:  2015-11-15       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.